oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Oral Semaglutide Reduces Cardiovascular Events in People New Science Suggests Semaglutide Improves

By Lana Pine | Published on February 12, 2025 5 min read Over nine weeks, individuals who took once-weekly low-dose semaglutide a glucagon-like peptide 1 (GLP-1) receptor agonist often used for diabetes and weight loss drank less alcohol in a lab test, had lower alcohol cravings and smoked fewer cigarettes (if they were smokers)

This hormone helps regulate blood sugar, slows down digestion, and tells your brain that you are full

Results so far are encouraging, showing a median relative change in BMI of -15 percent, visceral fat -19 percent, and FGV -22 percent, among other findings

Comparable to minoxidil. The frequently repeated assertion that a copper peptide performed comparably to 2% or 5% minoxidil in controlled trials traces, on inspection, to small or old studies, secondary summaries, and in some cases products that combined the peptide with other agents

Bland, protein-rich foods are usually better tolerated

Genetic data should complement clinical evaluation, not replace it